News from merrimack pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 04, 2015, 08:00 ET Merrimack Announces Presentations at the 2015 San Antonio Breast Cancer Symposium

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present on its innovative nanoliposomal platform for patients with...


Nov 23, 2015, 08:00 ET Merrimack and Baxalta Announce Publication of the ONIVYDE™ (irinotecan liposome injection) NAPOLI-1 Study in The Lancet

 Merrimack (Nasdaq: MACK) and Baxalta Incorporated (NYSE: BXLT) today jointly announced that The Lancet has published the article...


Nov 09, 2015, 16:02 ET Merrimack Reports Third Quarter 2015 Financial Results

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a biopharmaceutical company that applies systems biology to develop cancer treatments and...


Oct 27, 2015, 08:00 ET Merrimack and Baxalta Announce Enrollment of First Patient in Phase 2 Study of ONIVYDE™ (irinotecan liposome injection) in Previously Untreated Front-line Metastatic Pancreatic Cancer

Merrimack (Nasdaq: MACK) and Baxalta Incorporated (NYSE: BXLT) today jointly announced the enrollment of the first patient in an exploratory Phase...


Oct 22, 2015, 13:11 ET Merrimack Announces U.S. FDA Approval of ONIVYDE™ (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer

  Merrimack (Nasdaq: MACK) today announced that ONIVYDE™ (irinotecan liposome injection) has been approved by the U.S. Food and Drug...


Aug 10, 2015, 16:01 ET Merrimack Pharmaceuticals Reports Second Quarter 2015 Financial Results

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...


Aug 06, 2015, 08:00 ET Merrimack Pharmaceuticals Names Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that Yasir Al-Wakeel, MA, BM BCh will be appointed Chief Financial Officer and...


Aug 03, 2015, 08:00 ET Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its Second Quarter 2015 Investor Conference Call and...


Jun 25, 2015, 07:00 ET U.S. FDA Grants Priority Review for MM-398 New Drug Application

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) and Baxalta Incorporated, a wholly-owned subsidiary of Baxter International Inc (NYSE: BAX),...


Jun 15, 2015, 16:01 ET Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO of GE Healthcare, to Its Board of Directors

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the election of John M. Dineen to its Board of Directors. Dineen, the...


Jun 11, 2015, 17:00 ET Merrimack Pharmaceuticals Announces Expansion of MM-398 (nal-IRI) Imaging Study to Patients with Metastatic Breast Cancer

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the initiation of clinical imaging assessing the use of a potential marker...


Jun 01, 2015, 16:12 ET Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced data for MM-398 (irinotecan liposome injection), also known as...


May 14, 2015, 08:00 ET Merrimack Pharmaceuticals Announces Presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that data supporting further research and clinical development of MM-398 will...


May 07, 2015, 16:01 ET Merrimack Pharmaceuticals Reports First Quarter 2015 Financial Results

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...


May 05, 2015, 08:00 ET Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the initiation of a randomized, double-blinded, placebo-controlled Phase 2...


Apr 28, 2015, 16:15 ET Merrimack Pharmaceuticals Announces Timing of First Quarter 2015 Investor Conference Call and Presentation at Credit Suisse 2015 Antibody Conference

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will hold its First Quarter 2015 Investor Conference Call and...


Apr 27, 2015, 07:00 ET Merrimack Pharmaceuticals and Baxter BioScience Announce Completion of New Drug Application Submission to U.S. FDA for MM-398 as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) and Baxter International Inc. (NYSE: BAX) today jointly announced that Merrimack has completed the...


Apr 21, 2015, 08:00 ET First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced updated clinical data from a multi-arm Phase 1 study of MM-141, a bispecific...


Apr 20, 2015, 16:01 ET Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced updated and final clinical results for the Phase 1 study of MM-302, a novel HER2-targeted...


Mar 26, 2015, 08:00 ET Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present preclinical and clinical data showcasing its deep...